Moreover, the lack of post-ischemic administration in these studies leaves a significant gap in understanding the true therapeutic potential of Sig-1R activation in a clinical setting, where intervention typically occurs after ischemia has started [17, 18]. This evidence concerns the gene SIGMAR1 and ischemia.